Home  Contact Us
  Follow Us On:
Advertising Advertising Free Newsletter Free E-Newsletter

China's new recombinant COVID-19 vaccine starts human tests
Published on: 2021-04-28
Share to
User Rating: / 0

Sinopharm, the Chinese pharmaceutical giant, has commenced phase-1 and phase-2 clinical trials for its new recombinant vaccine against COVID-19 in central China's Henan Province since Saturday.

Developed by the China National Biotec Group (CNBG), a Sinopharm's bioscience subsidiary, the vaccine was issued with a clinical research permit from the National Medical Products Administration on April 9.

This is the CNBG's third COVID-19 vaccine candidate approved for human trials.

Researchers started the early-staged clinical trials in the city of Shangqiu, Henan Province. The trials were randomized, double-blind and placebo-controlled, according to a company statement.

Comments (0)Add Comment

Write comment

security code
Write the displayed characters

    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2021 BusinessTianjin.com. All rights reserved.